The Application of Peripheral Blood Immune Profiling in Personalized Treatment of Locally Advanced and Advanced Lung Cancer: A Nomogram Approach

Tianwen Yin¹Yikun Li²Qixin Sun³Qipeng Yuan²Shan Zhu⁴jinming yu²Tao Zhang¹FEIFEI TENG²Chuanwang Miao^2*

• ¹Huazhong University of Science and Technology, Wuhan, China
• ²Department of Radiation Oncology, Shandong Cancer Hospital, Jinan, China
• ³Shandong Second Medical University, Weifang, China
• ⁴Shandong Provincial ENT Hospital, Jinan, China

Immunotherapy has revolutionized the treatment of lung cancer, yet many patients experience limited or transient benefits. Identifying those most likely to benefit remains a critical challenge. This study aims to establish a predictive model based on peripheral blood lymphocyte subsets to evaluate treatment responses in locally advanced and advanced lung cancer patients receiving chemotherapy with or without immunotherapy.We prospectively enrolled 171 patients, peripheral blood lymphocyte subsets were analyzed pre-treatment, post-treatment, and at disease progression using flow cytometry, focusing on CD3 -CD16 + CD56 + cells, CD3 -CD19 + cells, CD3 + CD4 + T cells, CD4 + /CD8 + T-cell ratio, and CD3 + CD8 + T cells. We assessed correlations between these subsets and treatment efficacy and constructed a nomogram to predict outcomes.Baseline lymphocyte profiles were closely associated with treatment responses. Elevated CD3 -CD16 + CD56 + cells, increased CD4 + /CD8 + T cell ratio, and higher CD3 -CD19 + cells correlated with favorable treatment outcomes, particularly in patients receiving combined therapy. Conversely, higher CD3 + and CD3 + CD8 + T cell counts were linked to poorer short-term efficacy. A nomogram integrating five immune parameters achieved an area under the receiver operating characteristic curve (AUC) of 0.778, outperforming individual marker. In the combination therapy subgroup, a four-parameter model achieved an AUC of 0.725. Furthermore, baseline and progression-stage lymphocyte profiles in responder and non-responder cohorts, exhibit no significant differences, indicating stable immune parameters over the disease course.Peripheral blood lymphocyte subsets are promising non-invasive biomarkers for predicting treatment responses in locally advanced and advanced lung cancer patients, particularly with immunotherapy. The developed nomogram models enhance predictive accuracy, supporting personalized treatment decisions.